Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian Cancer (REBECA)

Yonsei University

Status: Completed

Conditions: Ovarian Cancer

Treatments: Drug: Bevacizumab; Drug: Pegylated liposomal doxorubicin; Drug: Weekly paclitaxel; Drug: Topotecan

Study type: Observational

Funder types: Other

Identifiers

NCT03367182

4-2017-0748

Details and patient eligibility

About

This study will evaluate the efficacy and safety profile, response rate, progression free survival, overall survival of bevacizumab (Avastin) added to chemotherapy in patients with epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma with disease progression within 6 months of platinum treatment.

Enrollment: 50 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients who have histologically or cytologically confirmed recurrent epithelial ovarian cancer, fallopian tube cancer, or peritoneal cancer.
2. Patients who have platinum-resistant disease (defined as having relapsed within 6 months of her last platinum-containing regimen)
3. Patients who have underwent chemotherapy of either weekly paclitaxel + bevacizumab, topotecan + bevacizumab, pegylated liposomal doxorubicin + bevacizumab in 2nd line or 3rd line chemotherapy.

Exclusion criteria

1. Patients with previous treatment with bevacizumab.
2. Patients who received bevacizumab combination therapy in 4th line or more chemotherapy.

Trial design

50 participants in 3 patient groups

Weekly paclitaxel + bevacizumab

Treatment:

Drug: Bevacizumab

Drug: Weekly paclitaxel

Topotecan + bevacizumab

Treatment:

Drug: Bevacizumab

Drug: Topotecan

Pegylated liposomal doxorubicin + bevacizumab

Treatment:

Drug: Bevacizumab

Drug: Pegylated liposomal doxorubicin